Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis

Zeina Al-Mansour*, Hongli Li, James R. Cook, Louis S. Constine, Stephen Couban, Douglas A. Stewart, Thomas C. Shea, Pierluigi Porcu, Jane N. Winter, Brad S. Kahl, Sonali M. Smith, Deborah C. Marcellus, Kevin P. Barton, Glenn M. Mills, Michael LeBlanc, Lisa M. Rimsza, Stephen J. Forman, John P. Leonard, Richard I. Fisher, Jonathan W. FriedbergPatrick J. Stiff

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Phase II data suggest a benefit to autotransplantation for aggressive T-cell non-Hodgkin lymphoma (T-NHL) in first remission; randomized trials have yet to validate this. We performed a retrospective analysis of aggressive T-NHL patients in the intergroup randomized consolidative autotransplant trial (SWOG 9704). Of the 370 enrolled, 40 had T-NHL: 12 were not randomized due to ineligibility (n = 1), choice (n = 2), or progression (n = 9), leaving 13 randomized to control and 15 to autologous stem cell transplantation (ASCT). Two ASCT patients refused transplant and one failed mobilization. The 5-year landmark PFS/OS estimates for ASCT vs. control groups were 40% vs. 38% (p =.56), and 40% vs. 45% (p =.98), respectively. No difference was seen based on IPI, or histologic subtype. Only 1/7 receiving BCNU-based therapy survived vs. 4/5 receiving TBI. Aggressive T-NHL autotransplanted in first remission did not appear to benefit from consolidative ASCT. This and the 30% who dropped out pre-randomization mostly to progression, suggests that improved induction regimens be developed.

Original languageEnglish (US)
Pages (from-to)1934-1941
Number of pages8
JournalLeukemia and Lymphoma
Volume60
Issue number8
DOIs
StatePublished - Jul 3 2019

Keywords

  • T-NHL treatment
  • consolidative autotransplant
  • high-risk T-NHL

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis'. Together they form a unique fingerprint.

  • Cite this

    Al-Mansour, Z., Li, H., Cook, J. R., Constine, L. S., Couban, S., Stewart, D. A., Shea, T. C., Porcu, P., Winter, J. N., Kahl, B. S., Smith, S. M., Marcellus, D. C., Barton, K. P., Mills, G. M., LeBlanc, M., Rimsza, L. M., Forman, S. J., Leonard, J. P., Fisher, R. I., ... Stiff, P. J. (2019). Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Leukemia and Lymphoma, 60(8), 1934-1941. https://doi.org/10.1080/10428194.2018.1563691